Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Pasithea Therapeutics (Nasdaq: KTTA) closes $5M public offering, adds $1.3M via warrant exercises, funding R&D for PAS-004 and other biotech innovations.
-
Pasithea Tx' PAS-004 shows up to 91% pERK inhibition in Phase 1 trial; one pancreatic cancer patient sees 4+ months stable disease and tumor shrinkage.
-
Pasithea’s PAS-004 cancer trial clears safety review; no DLTs or rash seen, advancing to 30mg dose in Phase 1 for MAPK-driven tumors.
-
Pasithea Therapeutics (KTTA) will present PAS-004 Phase 1 data at the 2025 CAGLA NeauxCancer Conference on March 28 in New Orleans.
-
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
-
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
Pasithea opens EU trial sites for PAS-004, doses Cohort 4, and plans interim safety data in Q1 2025.
-
Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile.
-
Pasithea Therapeutics' PAS-004 shows positive Phase 1 data: well-tolerated, no toxicities, promising efficacy in NF1 and MAPK-driven cancers.
-
Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.